Having validated the performance of its mass spec-based TIQUAS system for the identification of protein biomarkers in clinical samples, proteomics firm Activiomics is now aiming to step up its biomarker development efforts.

The firm is looking to both add to its internal biomarker pipeline, which is currently focused primarily on breast cancer, and to expand its service business to include collaborative companion diagnostic research, CEO Kevin FitzGerald told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.